WeChat Share

Boston BioForum 2016

Biomedical Innovations and Breakthroughs

Presented by

Chinese-American BioMedical Association (CABA)


CABA members: FREE; Non-members: $30. On-site membership registration available ($30 annual membership fee due). Dinner social reception: Regular: $60; student:$45.



Conference Organizing Committee:

Chair Bo Ying

Co-Chairs Carrie Liu, Wendy Yang, and Li Xing


For information about CABA and upcoming events, please check CABA Web site: www.cabaweb.org.


Date and Time

2016-04-30 09:00 - Start

2016-04-30 21:00 - End

  • Sanofi, 153 2nd Avenue , WALTHAM  MA  02451


Adam Koppel
Biogen, Executive Vice President
Adam Koppel is Executive Vice President, Strategy and Business Development and Chief Strategy Officer at Biogen, where he has served since May 2014. Previ ously, he was a managing director at Brookside Capital, the public equity affiliate of Bain Cap ital, which he joined in 2003. Prior to Brookside Capital, he was an associate principal of the McKinsey Hea lthcare Practice. Dr. Koppel holds Bachelor and Master of Arts degrees in History and Science from Har vard College and earned an M.D. and Ph.D. in Molecular Neurobiology from the University of P ennsylvania. He also received an M.B.A. from the University of Pennsylvania ’ s Wharton School. Dr. Koppel currently serves on the Board of Directors of PTC Therapeutics. He is also a member of the Board o f Directors of Trevena, Inc.
Stephen M. Kelsey
Onkaido Therapeutics, President
Steve Kelsey is President of Onkaido Therapeutics, a wholly-owned subsidiary of Moderna Therapeutics focused on mRNA-based therapies for cancer. He was appointed to this role in July 2014. Prior to Onkaido he held positions as Senior VP, New Projects at Medivation, Executive VP of Research and Development and CMO at Geron Corporation, and VP of Hematology and Oncology and Exploratory Clinical Development at Genentech. He is a hematologic oncologist by training and held the position of Senior Lecturer in Hematology at Barts and the London, UK from 1993 to 2000. He received his BSc in Pharmacology, MB ChB and MD degrees from the University of Birmingham, UK. He is a Fellow of the Royal College of Physicians of London and a Fellow of the Royal College of Pathologists (UK).
Derin Keskin
Harvard Medical School/Dana Farber Cancer Institute, Instructor
Derin Keskin is an Instructor at Harvard Medical Sc hool/Dana Farber Cancer Institute and a Research Sc ientist II at Broad Institute. He is a T cell immunologist inv estigating vaccine development against viruses and cancers. He also teaches at Harvard Medical School and Boston U niversity. Derin graduated from Istanbul University Cerrahpasa Medical School in 1997 and earned his PhD studying IDO inhibition of T cell responses in the laboratory of Andrew Mellor at the Medical College of Georgia. H e did his postdoctoral studies in the laboratory of Jack Stro minger at Harvard University and later in the Labor atory of Ellis Reinherz at Dana Farber Cancer Institute.
Jun Wang
Shanghai Medicilon Inc., VP
Dr. Jun Wang, VP of Discovery Biology at Shanghai Medicilon Inc. Before joining Medicilon, Dr. Wang was the VP and Head of Biology at Sundia MediTech. Dr. Wang served at Merck & Co., Inc. for 9 years, leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company in Seattle as the head of biology section and served as an assistant professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has been invited by many corresponding author in leading scientific journals. Lately, Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, and Naito Foundation for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr. Wang got his BS in biophysics from Fudan University and received his Ph.D. in molecular biology and biochemistry from Kobe University (Japan). He had his post-doc training in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).
Rich Gregory
Immunogen, CSO & EVP for Research
Rich Gregory joined ImmunoGen as CSO & EVP for Research in January of 2015. I n this capacity he provides leadership and direction to the Research organization and is r esponsible for the generation of development candidates based upon ImmunoGen ’ s Antibody Drug Conjugate technology. Rich received his B.Sc. in Biochemistry from Virginia Tech, his Ph.D. in Biochemistry from UMass, and did his post-doctoral training in cancer genetics at the Worcester Foundation for Experimental Biology. In 1989, Rich joined Genzyme as a scientist in the protein engineering group. At Genzyme, Rich was the project leader for the cystic fibrosis (CF) program, where his group did the seminal work which showed how mutations in CFTR lead to cystic fibrosis. Over the ensuing years Rich held a number of leadership positions at Ge nzyme, including VP Gene Therapy and Portfolio Leader for the Cardiovascular Disease and Immunology t herapeutic areas. In 2003, he was appointed the Head of Research at Genzyme, with responsibility – fr om discovery to development – for all Genzyme therapeutic areas. Following Sanofi ’ s acquisition of Genzyme in 2011, Rich was appointed Head of the Sanofi-Genzyme R&D Center and in that capacity represented Genzyme R&D within the Sanofi Global R&D organization.
Karl Griswold
Stealth Biologics LLC, Co-Founder, CEO
Dr. Griswold is also a tenured Associate Professor of Bioengineering in the Thayer School of Engineering at Dartmouth. His work in the field of protein engineering has resulted in the development of new tools for protein deimmunization, enhanced microbial production systems, novel strategies for gene library construction, and new approaches to high throughput screening of recombinant protein libraries. He studied as a DOW Foundation Scholar at Texas State University, graduating summa cum laude in 1995. He received his Ph.D. from the University of Texas at Austin in 2005, and completed a postdoctoral fellowship under Professor George Georgiou at the University of Texas. Dr. Griswold’s recent honors include a “Teacher of the Year” award from the Thayer School of Engineering and a “Young Investigator Award in Translational Biomedical Engineering” from the Coulter Foundation. He has coauthored more than 40 peer-reviewed articles and has patented inventions relating to both synthetic chemistry and biotechnology. He co-founded and serves as the CEO of the biotechnology startup Stealth Biologics, which has developed proprietary biotherapeutic design and deimmunization platforms that are advancing programs with numerous biopharma partners.
Richard Soll
International Discovery Service Unit WuXi AppTec, Senior Vice President
Dr. Richard Soll leads the WuXi offices in Cambridge, Massachusetts and in Israel to bring WuXi’s comprehensive platform of integrated R&D services closer to innovative companies and entrepreneurs in the world’s two leading biotech hubs. Dr. Soll’s contributions to drug discovery and development led to the discovery of the HCV breakthrough therapy Zepatier, the JAK2 inhibitor fedratinib, and more than 10 other clinical stage drugs. Dr. Soll has co-authored more than 100 patents and papers. Dr. Soll serves on the board of the Accelerator and has been an SAB member to biotech companies and advisor to entrepreneurs. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard.
David Wang
Medtronic, Vice President of Corporate Strategy
David Wang currently serves as Vice President of Strategy, Insights and Portfolio Management for Medtronic Corporate. Previously, David was Vice President of Strategy and BD& L for both Surgical Solutions Group and Vascular Therapies. He joined Covidien in 2010 after hol ding positions of increasing global marketing and strategic responsibility in the Cordis cardiovascu lar and DePuy neuroscience businesses of Johnson & Johnson. Before joining Johnson & Johnson i n 2003, David served in various leadership positions at McKinsey & Company and at the University of C hicago ’ s Biological Sciences Division of Academic Computing in Bioinformatics. David received both his bachelor ’ s degree in biological sciences and Master of Business Administration degree in finance fro m the University of Chicago.
John Tan
Kelun US Pharmaceutical Research Institute, President
Dr. John Tan is President of Kelun US Pharmaceutical Research Institute (KUPRI), a subsidiary of Kelun Pharmaceutical Group, that he joined in 2015. Currently Kelun has annual sales over 37B RMB, considered as one of China’s top pharmaceutical companies with 30,000 staff members. In 2014, Kelun was ranked the 4th most innovative pharma pipeline in China by Thompson Reuters. KUPRI consists of four functional sectors: biologics drug discovery, small-molecule drug discovery, US generic drug R&D and global business development. In this role, Dr. Tan oversees Kelun’s US operation and global BD. Previously Dr. Tan joined Merck & Co in 2001 where he has managed various drug discovery and alliance partner program teams, spanning across areas of oncology, cardiovascular, diabetes, antibiotics, endocrinology, and CNS. Prior to that, he was a research fellow at Memorial Sloan-Kettering Cancer Center in New York. Dr. Tan received a Ph. D. from Columbia University.

Meeting Agenda

2016-04-30 09:00 ~21:00
Meeting Agenda

09:00 - 10:00 am         Registration / Vendor Show

10:00 - 10:05 am         Opening Remarks, Bo Ying, Ph.D.,Conference Chair

10:05 - 10:15 am         Introduction of CABA, Susan Qu, Ph.D., President, CABA


10:15 - 11:00 am     

KEYNOTE SPEECH: Providing Patients with Access to the Promise of Gene Therapy: A US Perspective. 

Adam Koppel, MD, PhD, MBA, Executive Vice President and Chief Strategy Officer, Biogen

SESSION I – Immunotherapy: The Holy Grail for Cancer Treatment?


11:00 - 11:35 am

Nucleic Acid-Based Therapeutics in Oncology and Immuno-oncology. 

Stephen Kelsey, MD FRCP FRCPath, President, Onkaido Therapeutics, A Moderna Venture

11:35 - 12:10 pm                    

Cancer vaccines: Current Status and Future Directions. 

Derin Keskin, Ph.D., Research Scientist II, Broad Institute and Instructor, Harvard Medical School/Dana Farber Cancer Institute


LUNCH AND VENDOR SHOW: 12:10 – 01:30 pm (boxed lunch provided for all attendees)



12:45 - 01:15 pm                     

Luncheon Presentation: Outlook of Pharma/CRO industry in China. 

Jun Wang, Ph.D., Vice President, Shanghai Medicilon


SESSION II – Innovations in Technology


01:30 - 2:05 pm                        

Innovations in Antibody Drug Conjugate R&D. 

Richard Gregory, Ph.D., Executive Vice President and Chief Scientific Officer, Immunogen 

02:05 - 02:40pm

Biotherapeutic Immunogenicity: Opportunities for Biobetters and Innovative Biologics. 

Karl Griswold, Ph.D., CEO, Stealth Biologics




SESSION III –Trends in Market and Science


03:15 - 03:50pm

Platforms, Patients and Possibilities. 

Richard Soll, Ph.D., Senior Vice President, Wuxi AppTec

03:50- 04:25 pm 

Market Trends for Gene Sequencing, Bioinformatics or Gene Diagnostics. 

David Wang, MBA, Group Vice President, Medtronics

04:25 - 05:00pm                     

Drive Biopharmaceutical Innovation in and Beyond China. 

John Tan, President, Kelun US Pharmaceutical Research Institute


SOCIAL AND NETWORKING: 05:00 – 06:00 pm (Hors d’oeuvres provided)


06:00 - 06:45 pm     

KEYNOTE SPEECH: The Resurgence of Covalent Drugs. 

Juswinder Singh, Ph.D., President and Chief Scientific Officer, Ankaa Therapeutics


06:45 - 07:30 pm        CABA Announcement

07:30 - 09:00 pm        Social and Networking 



Type Sales End Price Quantity


2016-04-30 21:00 $15

About CABA

Chinese-American BioMedical Association (CABA) is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. 

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.


Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *